Abl1 Protein (Abl1 Tyrosine Kinase) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Abl1 Protein (Abl1 Tyrosine Kinase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox-protein
!! colspan="2" style="background:#f8f9fa; text-align:center; font-weight:bold" | ABL1 Protein (ABL1 Tyrosine Kinase)
|-
! Gene
! UniProt
! PDB Structures
| 1AB2, 2FO0, 4MVG, 6AMN |
|---|
! Molecular Weight
| ~120 kDa (including regulatory regions) |
|---|
! Subcellular Localization
| Cytoplasm, nucleus |
|---|
! Protein Family
| Tyrosine Kinase |
|---|
ABL1 is a non-receptor tyrosine kinase with SH3, SH2, kinase domains, and C-terminal regulatory regions. It exists in inactive and active conformations regulated by autophosphorylation.
ABL1 regulates actin cytoskeleton, cell adhesion, and stress responses. It is involved in DNA damage response and cell cycle control. In neurons, ABL1 may regulate axonal guidance and synaptic plasticity.
Imatinib (ABL1 inhibitor) shows neuroprotective effects in PD models. ABL1 is activated in response to cellular stress and may contribute to neurodegeneration. In AD, ABL1 activation may occur in response to A-beta.
Imatinib has been repurposed for neuroprotection in PD. Other ABL inhibitors (nilotinib, bosutinib) are being investigated. Challenges include blood-brain barrier penetration.
Abl1 Protein (Abl1 Tyrosine Kinase) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Abl1 Protein (Abl1 Tyrosine Kinase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.